Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03791216 · ClinicalTrials.gov registry record
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment
A clinical trial of Psoriasis, sponsored by Northwestern University.
- Completed
- Registry status
- 62
- Enrollment target
- 1
- Study location
NCT03791216: Completed study of Psoriasis, sponsored by Northwestern University.
NCT03791216 is a study of Psoriasis that has completed, run by Northwestern University. The registered enrollment target is 62 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03791216, a study of Psoriasis, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess differences in inflammatory proteins, lipoprotein composition, cholesterol efflux and HDL-proteome in moderate-to-severe pediatric psoriasis who at baseline begin systemically administered therapy vs: a) healthy controls; and b) patients with milder psoriasis.
Primary Outcome
To assess differences in the blood concentration levels at baseline for glucose in moderate-to-severe pediatric psoriasis at baseline who begin systemically administered therapy vs: a) healthy controls; and b) patients with milder psoriasis.
Conditions Studied
Interventions
- OTHER Fasting blood draw for lipid assessments
Study Locations (1)
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2025-06-18 |
What the finished NCT03791216 record still lists
NCT03791216 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Fasting blood draw for lipid assessments is the first listed.
NCT03791216 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03791216 about?
NCT03791216 is a clinical study titled "Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment". This study will assess differences in inflammatory proteins, lipoprotein composition, cholesterol efflux and HDL-proteome in moderate-to-severe pediatric psoriasis who at baseline begin systemically administered therapy vs: a) healthy controls; and b) patients with milder psoriasis.
What is the current status of trial NCT03791216?
This trial is currently completed. The enrollment target is 62 participants. The study started on 2018-12-01. Estimated completion is 2025-06-18.
What conditions does trial NCT03791216 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03791216?
The interventions under investigation include: Fasting blood draw for lipid assessments (OTHER).
Who is sponsoring clinical trial NCT03791216?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03791216 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03791216's enrollment target sits among peer trials
62 70th of 125 higher than 56 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI